FDA extends PDUFA Target Action Date and continues review of deramiocel BLA – Capricor Therapeutics
Capricor Therapeutics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational… read more.
